INT12891

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 1989
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 41
Total Number 41
Disease Relevance 17.99
Pain Relevance 15.06

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (MMP3) extracellular space (MMP3) extracellular region (MMP3)
proteinaceous extracellular matrix (MMP3) nucleus (MMP3) protein complex (MMP3)
Anatomy Link Frequency
cartilage 3
macrophage 1
synovial fluid 1
chondrocytes 1
1A2 1
MMP3 (Homo sapiens)
Pain Link Frequency Relevance Heat
metalloproteinase 490 100.00 Very High Very High Very High
diclofenac 2 99.80 Very High Very High Very High
imagery 49 99.78 Very High Very High Very High
Adalimumab 266 99.44 Very High Very High Very High
rheumatoid arthritis 142 99.26 Very High Very High Very High
spinal inflammation 402 99.12 Very High Very High Very High
Pain score 39 99.04 Very High Very High Very High
Paracetamol 11 98.24 Very High Very High Very High
cytokine 88 96.64 Very High Very High Very High
Osteoarthritis 430 96.28 Very High Very High Very High
Disease Link Frequency Relevance Heat
Osteoarthritis 341 99.48 Very High Very High Very High
Rheumatoid Arthritis 147 99.26 Very High Very High Very High
Seronegative Spondarthritis 28 99.12 Very High Very High Very High
Pain 175 98.90 Very High Very High Very High
Low Back Pain 407 98.52 Very High Very High Very High
Fibrosis 7 97.76 Very High Very High Very High
Disease 219 96.96 Very High Very High Very High
Adenocarcinoma 67 94.84 High High
Cancer 166 94.64 High High
Arthritis 203 94.44 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The statistical analyses revealed that the improvements in physical parameters and reductions in synovial MMP-3 levels were significantly decreased in the treatment groups as compared with the placebo group (Figures 2 and 3).
Negative_regulation (reductions) of MMP-3
1) Confidence 0.58 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2575633 Disease Relevance 1.01 Pain Relevance 0.63
ASUs stimulate aggrecan synthesis while inhibiting stromelysin activity in osteoarthritic chondrocytes (14).
Negative_regulation (inhibiting) of stromelysin in chondrocytes associated with osteoarthritis
2) Confidence 0.57 Published 2008 Journal Evidence-based Complementary and Alternative Medicine : eCAM Section Body Doc Link PMC2396479 Disease Relevance 0.72 Pain Relevance 0.33
The IL-1beta-mediated induction of MMP-1 mRNA expression was attenuated by 10 microg/ml HA (p=0.026) and that of MMP-3 mRNA was strongly down-regulated in the presence of 10 or 1000 microg/ml HA (p<0.001).
Negative_regulation (down-regulated) of MMP-3 mRNA associated with metalloproteinase
3) Confidence 0.52 Published 2004 Journal Tohoku J. Exp. Med. Section Abstract Doc Link 15383690 Disease Relevance 0.21 Pain Relevance 0.90
Acetaminophen and ketoprofen had no effect; sodium salicylate, indomethacin, and diclofenac slightly decreased proteoglycanase activity.
Negative_regulation (decreased) of proteoglycanase associated with paracetamol and diclofenac
4) Confidence 0.49 Published 1991 Journal Arthritis Rheum. Section Abstract Doc Link 1657006 Disease Relevance 0.43 Pain Relevance 0.23
Aflapin exhibited better 5-lipoxygenase inhibitory activity and MMP-3 inhibition.
Negative_regulation (inhibition) of MMP-3
5) Confidence 0.48 Published 2010 Journal International Journal of Medical Sciences Section Body Doc Link PMC2974165 Disease Relevance 0.50 Pain Relevance 0.27
TNFalpha antagonist therapy induces a significant decrease in MMP-3 levels, together with decreases in conventional variables (ESR, CRP, and BASDAI).
Negative_regulation (decrease) of MMP-3
6) Confidence 0.47 Published 2008 Journal Joint Bone Spine Section Body Doc Link 18674944 Disease Relevance 0 Pain Relevance 0
Tiaprofenic acid induced in vitro a concomitant increase in PLA2 and a decrease in proteoglycanase activity.
Negative_regulation (decrease) of proteoglycanase
7) Confidence 0.44 Published 1989 Journal J Rheumatol Suppl Section Abstract Doc Link 2553968 Disease Relevance 0.32 Pain Relevance 0.13
Corroborating the improvements in pain scores in treatment groups, we also noted significant reduction in synovial fluid matrix metalloproteinase-3.
Negative_regulation (reduction) of matrix metalloproteinase-3 in synovial fluid associated with pain score and metalloproteinase
8) Confidence 0.43 Published 2008 Journal Arthritis Res Ther Section Abstract Doc Link PMC2575633 Disease Relevance 1.02 Pain Relevance 0.81
RESULTS: There was a significant increase in collagenase-3 (MMP-13) mRNA levels, a decrease in stromelysin-1 (MMP-3) mRNA levels, and a decrease in tissue inhibitor of metalloproteinase-2, -3, and -4 mRNA levels.
Negative_regulation (decrease) of stromelysin-1
9) Confidence 0.42 Published 2004 Journal Am J Sports Med Section Body Doc Link 15262646 Disease Relevance 0 Pain Relevance 0
RESULTS: There was a significant increase in collagenase-3 (MMP-13) mRNA levels, a decrease in stromelysin-1 (MMP-3) mRNA levels, and a decrease in tissue inhibitor of metalloproteinase-2, -3, and -4 mRNA levels.
Negative_regulation (decrease) of stromelysin-1
10) Confidence 0.42 Published 2004 Journal Am J Sports Med Section Body Doc Link 15262646 Disease Relevance 0 Pain Relevance 0
No statistical correlation was found between p40 IL12/40 serum levels and each of BASDAI, ESR, CRP, serum levels of IL 17, MMP 3.
Negative_regulation (levels) of MMP 3
11) Confidence 0.41 Published 2009 Journal Clin. Rheumatol. Section Abstract Doc Link 18827961 Disease Relevance 0.52 Pain Relevance 0.29
Nimesulide significantly reduced the serum levels of both HA and MMP-3, whereas ibuprofen increased moderately but significantly the serum concentrations of MMP-3 and had no effect on the serum concentrations of HA.
Negative_regulation (reduced) of MMP-3
12) Confidence 0.39 Published 2004 Journal Int J Clin Pract Suppl Section Abstract Doc Link 16035398 Disease Relevance 0.32 Pain Relevance 0.46
In adalimumab recipient, radiographic progression is also controlled and serum levels of matrix metalloproteinase-1(MMP-1) and MMP-3 decrease.
Negative_regulation (decrease) of MMP-3 associated with metalloproteinase and adalimumab
13) Confidence 0.38 Published 2002 Journal Nippon Rinsho Section Abstract Doc Link 12510366 Disease Relevance 0.39 Pain Relevance 0.34
The increased protein levels of MMP-1 and MMP-3 were also reduced by 1000 microg/ml HA.
Negative_regulation (reduced) of MMP-3 associated with metalloproteinase
14) Confidence 0.38 Published 2004 Journal Tohoku J. Exp. Med. Section Abstract Doc Link 15383690 Disease Relevance 0.19 Pain Relevance 0.89
Compared with the placebo group, the low-dose (100 mg) and high-dose (250 mg) 5-Loxin® groups showed 31.37% (P = 0.002) and 46.4% (P < 0.001) reductions in MMP-3 concentration, respectively.
Negative_regulation (reductions) of MMP-3
15) Confidence 0.37 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2575633 Disease Relevance 0.20 Pain Relevance 0.10
A decrease of MMP-3 levels during treatment with TNF-?
Negative_regulation (decrease) of MMP-3
16) Confidence 0.37 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2592815 Disease Relevance 0.53 Pain Relevance 0.59
Accordingly, a decrease of VEGF and MMP-3 serum levels was observed: serum levels of VEGF were 324.6 ± 179.8 pg/mL before therapy and decreased significantly to 277.1 ± 155.37 pg/mL after 12 weeks and to 250.7 ± 120.8 pg/mL after 36 to 52 weeks of therapy (P < 0.001).
Negative_regulation (decrease) of MMP-3
17) Confidence 0.37 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2592815 Disease Relevance 0.29 Pain Relevance 0.09
On day 84, there was no significant decrease in biomarker levels in the placebo group, whereas significant reductions in the levels of both MMP-3 and hyaluronan were observed in the 2 sCT groups.
Negative_regulation (reductions) of MMP-3
18) Confidence 0.36 Published 2006 Journal Arthritis Rheum. Section Body Doc Link 17009253 Disease Relevance 0.06 Pain Relevance 0
Piroxicam and tenoxicam suppressed proteoglycanase activity by 48.2% and 68.3%, respectively, and suppressed collagenase activity by 19.1% and 36.8%, respectively.
Negative_regulation (suppressed) of proteoglycanase
19) Confidence 0.36 Published 1991 Journal Arthritis Rheum. Section Abstract Doc Link 1657006 Disease Relevance 0.42 Pain Relevance 0.23
These genes included osteonectin (SPARC), fibronectin (FN1), versican (CSPG2), and collagen type 1A2 (COL1A2), tissue inhibitor of metalloproteinase 1 (TIMP1), biglycan (BGN), matrix metalloproteinase 2 (MMP2), and stromelysin-1 (MMP3) [5], [36]–[38].
Negative_regulation (inhibitor) of stromelysin-1 in 1A2 associated with metalloproteinase
20) Confidence 0.36 Published 2007 Journal PLoS ONE Section Body Doc Link PMC1824711 Disease Relevance 1.51 Pain Relevance 0.10

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox